Skip to content
HowShorted

Phathom Pharmaceuticals, Inc. short interest in 2020

In 2020, Phathom Pharmaceuticals, Inc.'s disclosed short interest ran from 3.40% of shares outstanding on 15 Apr 2020 to 2.79% on 31 Dec 2020, a change of -0.61 percentage points. The year's high was 4.30% on 30 Jun 2020 and its low 2.30% on 15 Dec 2020, averaging 3.20% across 18 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 32.07 days on 30 Apr 2020. Full history: Phathom Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Phathom Pharmaceuticals, Inc. in 2020

2020 in figures

Start of year
3.40% (15 Apr 2020)
End of year
2.79% (31 Dec 2020)
Change
-0.61 pp
High
4.30% (30 Jun 2020)
Low
2.30% (15 Dec 2020)
Average
3.20%
Highest days to cover
32.07 (30 Apr 2020)
SEC filings marked
8

Every report in 2020

Phathom Pharmaceuticals, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Apr 20203.40%18.1810-K filed, results (8-K)
30 Apr 20203.40%32.07
15 May 20203.46%23.0010-Q filed, results (8-K)
29 May 20203.53%14.25
15 Jun 20203.51%12.75
30 Jun 20204.30%7.47
15 Jul 20204.15%23.18
31 Jul 20203.66%22.09
14 Aug 20203.18%22.2710-Q filed, results (8-K)
31 Aug 20203.01%23.85
15 Sep 20202.88%23.13
30 Sep 20202.82%17.47
15 Oct 20202.87%16.69
30 Oct 20202.88%28.54
13 Nov 20202.77%13.1010-Q filed, results (8-K)
30 Nov 20202.63%16.19
15 Dec 20202.30%9.34
31 Dec 20202.79%2.30

See also: Phathom Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.